Specific changes of serum proteins in Parkinson's disease patients

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Lu, Wenwen ^a   Wan, Xinhua ^b   Liu, Bin ^a   Rong, Xianfang ^a   Zhu, Lei ^a   Li, Pingping ^a   Li, Jiang ^a   Wang, Ling ^a   Cui, Liying ^b   Wang, Xiaoliang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN GAMMA CHAIN; INTER ALPHA TRYPSIN INHIBITOR HEAVY CHAIN H4; MEMBRANE PROTEIN; PLASMA PROTEIN; UNCLASSIFIED DRUG; APOLIPOPROTEIN A; APOLIPOPROTEIN A-IV; BIOLOGICAL MARKER; FIBRINOGEN; FIBRINOPEPTIDES GAMMA; GLYCOPROTEIN; ITIH4 PROTEIN, HUMAN; LEUKOCYTE ELASTASE INHIBITOR;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MIDDLE AGED; PARKINSON DISEASE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING; BLOOD; CASE CONTROL STUDY; FEMALE; METABOLISM;

APOLIPOPROTEINS A; BIOLOGICAL MARKERS; BLOOD PROTEINS; CASE-CONTROL STUDIES; FEMALE; FIBRINOGEN; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PROTEINASE INHIBITORY PROTEINS, SECRETORY;

EID: 84899734378     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095684     Document Type: Article

References (53)

1. Gille G, Hung ST, Reichmann H, Rausch WD (2004) Oxidative stress to dopaminergic neurons as models of Parkinson's disease. Ann N Y Acad Sci 1018:533-540. (Pubitemid 38951450)
2. Jankovic J, Rajput AH, McDermott MP, Perl DP (2000) The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol 57(3):369-372. (Pubitemid 30140525)
3. Tolosa E, Wenning G, Poewe W (2006) The diagnosis of Parkinson's disease. Lancet Neurol 5(1):75-86. (Pubitemid 41790698)
4. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047. (Pubitemid 27443610)
5. Markopoulou K, Langston JW (1999) Candidate genes and Parkinson's disease: where to next? Neurology 53(7):1382-1383. (Pubitemid 29491924)
6. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18(2):106-108.
7. McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P (2001) Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci 2(8):589-594. (Pubitemid 33679832)
8. Owen AD, Schapira AH, Jenner P, Marsden CD (1996) Oxidative stress and Parkinson's disease. Ann N Y Acad Sci 786:217-223. (Pubitemid 26273166)
9. Xie H, Chang M, Hu X, Wang D, Tian M, et al. (2011) Proteomics analysis of MPP+-induced apoptosis in SH-SY5Y cells. Neurol Sci 32(2):221-228.
10. Mila S, Albo AG, Corpillo D, Giraudo S, Zibetti M, et al. (2009) Lymphocyte proteomics of Parkinson's disease patients reveals cytoskeletal protein dysregulation and oxidative stress. Biomark Med 3(2):117-128.
11. Rite I, Arguelles S, Venero JL, Garcia-Rodriguez S, Ayala A, et al. (2007) Proteomic identification of biomarkers in the cerebrospinal fluid in a rat model of nigrostriatal dopaminergic degeneration. J Neurosci Res 85(16):3607-3618. (Pubitemid 350228706)
12. Pandey A, Mann M (2000) Proteomics to study genes and genomes. Nature 405:837-846. (Pubitemid 30407862)
13. Zhao X, Xiao WZ, Pu XP, Zhong LJ (2010) Proteome analysis of the sera from Chinese Parkinson's disease patients. Neuroscience Letters 479(2):175-179.
14. Guo J, Sun Z, Xiao S, Liu D, Jin G, et al. (2009) Proteomic analysis of the cerebrospinal fluid of Parkinson's disease patients. Cell Res 19(12):1401-1403.
15. Goldknopf IL, Bryson JK, Strelets I, Quintero S, Sheta EA, et al. (2009) Abnormal serum concentrations of proteins in Parkinson's disease. Biochem Biophys Res Commun 389(2):321-327.
16. Chung YC, Ko HW, Bok E, Park ES, Huh SH, et al. (2010) The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Rep 43(4):225-232.
17. Karp NA, McCormick PS, Russell MR, Lilley KS (2007) Experimental and statistical considerations to avoid false conclusions in proteomics studies using differential in-gel electrophoresis. Mol Cell Proteomics 6:1354-1364. (Pubitemid 47365434)
18. Yang MH, Yang YH, Lu CY, Jong SB, Chen LJ, et al. (2012) Activity-dependent neuroprotector homeobox protein: A candidate protein identified in serum as diagnostic biomarker for Alzheimer's disease. J Proteomics 75(12):3617-3629.
19. Cui Y, Huang M, He Y, Zhang S, Luo Y (2011) Genetic ablation of apolipoprotein A-IV accelerates Alzheimer's disease pathogenesis in a mouse model. Am J Pathol 178(3):1298-1308.
20. Gerlach M, Maetzler W, Broich K, Hampel H, Rems L, et al. (2012) Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm 119(1)39-52.
21. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, et al. (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133(3): 713-726.
22. Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, et al. (2006) Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 349(1): 162-166. (Pubitemid 44331776)
23. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, et al. (2008) Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213(2): 315-325.
24. Ohrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E, et al. (2009) Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 450(3): 332-335.
25. Basso M, Giraudo S, Corpillo D, Bergamasco B, Lopiano L, et al. (2004) Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 4(12):3943-3952. (Pubitemid 39657469)
26. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, et al. (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 279(13):13256-13264. (Pubitemid 38445905)
27. De Iuliis A, Grigoletto J, Recchia A, Giusti P, Arslan P (2005) A proteomic approach in the study of an animal model of Parkinson's disease. Clin Chim Acta 357(2):202-209. (Pubitemid 40894638)
28. Sinha A, Srivastava N, Singh S, Singh AK, Bhushan S, et al. (2009) Identification of differentially displayed proteins in cerebrospinal fluid of Parkinson's disease patients: a proteomic approach. Clin Chim Acta 400:14-20.
29. Wang ES, Sun Y, Guo JG, Gao X, Hu JW, et al. (2010) Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson's disease. Acta Neurol Scand 122(5):350-359.
30. Ishida Y, Nagai A, Kobayashi S, Kim SU (2006) Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase. J Neuropathol Exp Neurol 65(1):66-77.
31. Wong KT, Grove JS, Grandinetti A, Curb JD, Yee M, et al. (2010) Association of Fibrinogen with Parkinson Disease in Elderly Japanese-American Men: A Prospective Study. Neuroepidemiology 34(1):50-54.
32. Maarouf CL, Beach TG, Adler CH, Shill HA, Sabbagh MN, et al. (2012) Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects. Neurol Res 34(7):669-676.
33. Kamath S, Lip GY (2003) Fibrinogen: biochemistry, epidemiology and determinants. QJM 96(10):711-729. (Pubitemid 37259361)
34. Ugarova TP, Yakubenko VP (2001) Recognition of fibrinogen by leukocyte integrins. Ann N Y Acad Sci 936:368-385. (Pubitemid 32613922)
35. Mosesson MW (2003) Fibrinogen gamma chain functions. J Thromb Haemost 1(2):231-238.
36. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A (2008) Peripheral Inflammatory Biomarkers and Risk of Parkinson's Disease. Am J Epidemiol 167(1):90-95.
37. Hald A, Van Beek J, Lotharius J (2007) Inflammation in Parkinson's disease: causative or epiphenomenal? Subcell Biochem 42:249-279.
38. Hald A, Lotharius J (2005) Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol 193(2):279-290. (Pubitemid 40616179)
39. Asanuma M, Miyazaki I, Ogawa N (2004) Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases. Curr Pharm Des 10(6):695-700. (Pubitemid 38292397)
40. Klegeris A, McGeer EG, McGeer PL (2007) Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol 20(3):351-357. (Pubitemid 46743120)
41. Tansey MG, McCoy MK, Frank-Cannon TC (2007) Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 208(1):1-25. (Pubitemid 47603240)
42. Tso P, Liu M, Kalogeris TJ, Thomson AB (2001) The role of apolipoprotein A-IV in the regulation of food intake. Annu Rev Nutr 21:231-254. (Pubitemid 32695271)
43. Fujimoto K, Fukagawa K, Sakata T, Tso P (1993) Suppression of food intake by apolipoprotein A-IV is mediated through the central nervous system in rats. J Clin Invest 91(4):1830-1833. (Pubitemid 23127391)
44. Park JY, Park JH, Jang W, Hwang IK, Kim IJ, et al. (2012) Apolipoprotein A-IV is a novel substrate for matrix metalloproteinases. J Biochem 151(3):291-298.
45. Piñeiro M, Alava MA, González-Ramón N, Osada J, Lasierra P, et al. (1999) ITIH4 serum concentration increases during acute-phase processes in human patients and is up-regulated by interleukin-6 in hepatocarcinoma HepG2 cells. Biochem Biophys Res Commun 263(1):224-229. (Pubitemid 29443667)
46. Gonzalez-Ramon N, Alava MA, Sarsa JA, Pineiro M, Escartin A, et al. (1995) The major acute phase serum protein in pigs is homologous to human plasma kallikrein sensitive PK-120. FEBS Lett 371(3):227-230.
47. Diamandis EP (2006) Peptidomics for cancer diagnosis: present and future. J Proteome Res 5(9):2079-2082.
48. Wang Z, Yip C, Ying Y, Wang J, Meng XY, et al. (2004) Mass spectrometric analysis of protein markers for ovarian cancer. Clin Chem 50(10):1939-1942.
49. Tanaka H, Shimazawa M, Takata M, Kaneko H, Tsuruma K, et al. (2013) ITIH4 and Gpx3 are potential biomarkers for amyotrophic lateral sclerosis. J Neurol 260(7):1782-1797.
50. Kim MS, Gu BH, Song S, Choi BC, Cha DH, et al. (2011) ITI-H4, as a biomarker in the serum of recurrent pregnancy loss (RPL) patients. Mol Biosyst 7(5):1430-1440.
51. Alberio T, Pippione AC, Comi C, Olgiati S, Cecconi D, et al. (2012) Dopaminergic therapies modulate the T-CELL proteome of patients with Parkinson's disease. IUBMB Life 64(10):846-852.
52. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181-184.
53. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100:9440-9445. (Pubitemid 37033947)